Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03032835 · ClinicalTrials.gov registry record

Partners Calciphylaxis Biobank

A clinical trial of End Stage Renal Disease and Chronic Kidney Diseases, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT03032835 is a study of End Stage Renal Disease and Chronic Kidney Diseases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 300 participants, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03032835, a study of End Stage Renal Disease and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis. The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2017-01
Est. Completion 2030-12

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03032835

The ClinicalTrials.gov registry entry for NCT03032835 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (64% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03032835 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03032835 about?

NCT03032835 is a clinical study titled "Partners Calciphylaxis Biobank". Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pat...

What is the current status of trial NCT03032835?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-01. Estimated completion is 2030-12.

What conditions does trial NCT03032835 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy.

Who is sponsoring clinical trial NCT03032835?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03032835 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.